C Day
C Day
Dirección de correo verificada de ncl.ac.uk
Citado por
Citado por
Steatohepatitis: a tale of two “hits”?
CP Day, OFW James
Gastroenterology 114 (4), 842-845, 1998
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
CP Day, JM McComb, RW Campbell
Heart 63 (6), 342-344, 1990
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
G Targher, CP Day, E Bonora
New England Journal of Medicine 363 (14), 1341-1350, 2010
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
GP Aithal, CP Day, PJL Kesteven, AK Daly
The Lancet 353 (9154), 717-719, 1999
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
QM Anstee, G Targher, CP Day
Nature reviews Gastroenterology & hepatology 10 (6), 330-344, 2013
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
G Targher, L Bertolini, R Padovani, S Rodella, R Tessari, L Zenari, C Day, ...
Diabetes care 30 (5), 1212-1218, 2007
The natural history of nonalcoholic fatty liver: a follow‐up study
MR Teli, OFW James, AD Burt, MK Bennett, CP Day
Hepatology 22 (6), 1714-1719, 1995
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of The Liver, ...
Obesity facts 9 (2), 65-90, 2016
HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
Non-alcoholic fatty liver disease: the mist gradually clears
NMW de Alwis, CP Day
Journal of hepatology 48, S104-S112, 2008
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management
S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee
Journal of hepatology 62 (5), 1148-1155, 2015
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
S McPherson, SF Stewart, E Henderson, AD Burt, CP Day
Gut 59 (9), 1265-1269, 2010
Pathogenesis of steatohepatitis
CP Day
Best practice & research Clinical gastroenterology 16 (5), 663-678, 2002
Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis
AM Diehl, C Day
N Engl J Med 377, 2063-2072, 2017
EASL clinical practical guidelines: management of alcoholic liver disease
European Association For The Study Of The Liver
Journal of hepatology 57 (2), 399-420, 2012
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ...
Journal of hepatology 69 (4), 896-904, 2018
Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
L Valenti, A Al‐Serri, AK Daly, E Galmozzi, R Rametta, P Dongiovanni, ...
Hepatology 51 (4), 1209-1217, 2010
Prednisolone or pentoxifylline for alcoholic hepatitis
MR Thursz, P Richardson, M Allison, A Austin, M Bowers, CP Day, ...
New England Journal of Medicine 372 (17), 1619-1628, 2015
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20